Page last updated: 2024-11-03

propranolol and Primary Peritonitis

propranolol has been researched along with Primary Peritonitis in 27 studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Research Excerpts

ExcerptRelevanceReference
"It has been suggested that propranolol may have a protective effect on the development of spontaneous bacterial peritonitis by increasing the motility of the bowel and lowering the pressure of the portal vein."7.73Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? ( Archimandritis, AJ; Burroughs, AK; Cholongitas, E; Manesis, EK; Papatheodoridis, GV, 2006)
"Sclerosing peritonitis developed in a 56-year-old white man who had been receiving propranolol (320 mg/day) for hypertension and angina pectoris since December 1976."7.66Sclerosing peritonitis and propranolol. ( Ahmad, S, 1981)
"Sclerosing peritonitis developed in a 43-year-old man with angina pectoris who had been receiving the beta-adrenergic receptor antagonist, propranolol."7.66Sclerosing peritonitis and propranolol. ( Harty, RF, 1978)
"We assessed the impact of propranolol on death, risk of hepatorenal syndrome and peritonitis in patients with cirrhosis."3.83Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. ( Bang, UC; Bendtsen, F; Benfield, T; Hyldstrup, L; Jensen, JE, 2016)
"It has been suggested that propranolol may have a protective effect on the development of spontaneous bacterial peritonitis by increasing the motility of the bowel and lowering the pressure of the portal vein."3.73Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial? ( Archimandritis, AJ; Burroughs, AK; Cholongitas, E; Manesis, EK; Papatheodoridis, GV, 2006)
"Sclerosing peritonitis developed in a 56-year-old white man who had been receiving propranolol (320 mg/day) for hypertension and angina pectoris since December 1976."3.66Sclerosing peritonitis and propranolol. ( Ahmad, S, 1981)
"Sclerosing peritonitis developed in a 43-year-old man with angina pectoris who had been receiving the beta-adrenergic receptor antagonist, propranolol."3.66Sclerosing peritonitis and propranolol. ( Harty, RF, 1978)
"We studied the effects of alcohol and propranolol on the course of peritonitis in rabbits."3.66Propranolol antagonizes the anti-inflammatory effect of alcohol and improves survival of infected intoxicated rabbits. ( Buckley, RM; MacGregor, RR; Ventura, ES, 1978)
"Bacterial infections have been hypothetized to be a trigger of variceal bleeding in cirrhotic patients and beta-blockers may have a protective effect by decreasing bacterial translocation, reducing portal pressure."2.45beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. ( Burra, P; Burroughs, AK; Cholongitas, E; Leandro, G; Patch, D; Senzolo, M; Thalheimer, U, 2009)

Research

Studies (27)

TimeframeStudies, this research(%)All Research%
pre-199015 (55.56)18.7374
1990's1 (3.70)18.2507
2000's7 (25.93)29.6817
2010's4 (14.81)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bang, UC1
Benfield, T1
Hyldstrup, L1
Jensen, JE1
Bendtsen, F1
Senzolo, M3
Cholongitas, E3
Burra, P1
Leandro, G1
Thalheimer, U1
Patch, D1
Burroughs, AK4
Kalra, S1
Atia, A1
McKinney, J1
Borthwick, TR1
Smalligan, RD1
Fries, W1
Buda, A1
Pizzuti, D1
Nadal, E2
Sturniolo, GC1
D'Incà, R1
Wong, F1
Salerno, F1
Angeli, P1
Abraldes, JG1
Tarantino, I1
Turnes, J1
Garcia-Pagan, JC1
Rodés, J1
Bosch, J1
Soylu, AR1
Dökmeci, G1
Tezel, A1
Amuca, H1
Umit, H1
Papatheodoridis, GV1
Manesis, EK1
Archimandritis, AJ1
Youn, KH1
Kim, DJ1
Landman, MD1
Longmire, WP1
Nicholls, JT1
Rutty, DA1
Ing, TS1
Daugirdas, JT1
Gandhi, VC1
Marigold, JH1
Pounder, RE1
Pemberton, J1
Thompson, RP2
Ahmad, S1
Frishman, W1
Silverman, R1
Strom, J1
Elkayam, U1
Sonnenblick, E1
Harty, RF1
Buckley, RM1
Ventura, ES1
MacGregor, RR1
Benny, PS1
Denham, HE1
Panting, AL1
Jackson, BT1
Gurry, JF1
Cunningham, IG1
Brooke, BN1
Riabrsev, VG1
Iarema, IV1
Dzheĭranov, FD1
Mezvrishvili, GO1
Fil'chev, MI1
Sjöqvist, A1
Hallerbäck, B1
Glise, H1
Chepkiĭ, LP1
Pys'ko, SA1
Shemchuk, AS1
Kandel, G1
Diamant, NE1
Holzer, P1
Lippe, IT1
Holzer-Petsche, U1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study[NCT02123576]12 participants (Actual)Interventional2014-04-30Terminated (stopped due to Poor enrollment of study population)
Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy[NCT01851252]Phase 119 participants (Actual)Interventional2013-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Serum Creatinine From Baseline

(NCT02123576)
Timeframe: baseline and 14 days

Interventiong/dL (Mean)
Treatment0.48
Placebo0.03

Incidence of Treatment Failure

Defined as creatinine level above baseline value after day 7, dialysis or death (NCT02123576)
Timeframe: up to day 14

InterventionParticipants (Count of Participants)
Treatment3
Placebo3

Number of Participants With Combined Outcome of Treatment Success and Partial Response

We define as serum creatinine level decreased by >50% from baseline but not to <1.5 mg/dL, without dialysis or HRS recurrence (NCT02123576)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment1
Placebo2

Number of Participants With Treatment Success

We define this as a decrease in serum creatinine level to <1.5 mg/dL without dialysis or death (NCT02123576)
Timeframe: 14 days

InterventionParticipants (Count of Participants)
Treatment1
Placebo1

Overall Survival

This will be the combination of transplant free survival and those patients who received liver transplant (NCT02123576)
Timeframe: up to 1 year

Interventiondays (Mean)
Treatment102
Placebo59

Transplant Free Survival

(NCT02123576)
Timeframe: day 30 and 180

Interventiondays (Mean)
Treatment80
Placebo36

Reviews

3 reviews available for propranolol and Primary Peritonitis

ArticleYear
beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:8

    Topics: Adrenergic beta-Antagonists; Bacterial Infections; Bacterial Translocation; Databases, Bibliographic

2009
Sclerosing encapsulating peritonitis associated with propranolol usage: a case report and review of the literature.
    Journal of digestive diseases, 2009, Volume: 10, Issue:4

    Topics: Adrenergic beta-Antagonists; Humans; Intestinal Obstruction; Male; Middle Aged; Peritonitis; Propran

2009
A clinical view of recent advances in ascites.
    Journal of clinical gastroenterology, 1986, Volume: 8, Issue:1

    Topics: Animals; Ascites; Ascitic Fluid; Bacterial Infections; Blood Volume; Body Water; Extracellular Space

1986

Other Studies

24 other studies available for propranolol and Primary Peritonitis

ArticleYear
Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers.
    Liver international : official journal of the International Association for the Study of the Liver, 2016, Volume: 36, Issue:9

    Topics: Aged; Cause of Death; Databases, Factual; Denmark; Dose-Response Relationship, Drug; Female; Hepator

2016
Oral propranolol decreases intestinal permeability in patients with cirrhosis: another protective mechanism against bleeding?
    The American journal of gastroenterology, 2009, Volume: 104, Issue:12

    Topics: Adrenergic beta-Antagonists; Bacterial Translocation; Clinical Trials as Topic; Esophageal and Gastr

2009
Beta-blockers in cirrhosis: friend and foe?
    Hepatology (Baltimore, Md.), 2010, Volume: 52, Issue:3

    Topics: Adrenergic beta-Antagonists; Esophageal and Gastric Varices; Humans; Liver Cirrhosis; Peritonitis; P

2010
β-blockers and refractory ascites in cirrhosis: the message of a team of true scientists.
    Journal of hepatology, 2011, Volume: 55, Issue:4

    Topics: Adrenergic beta-Antagonists; Ascites; Bacterial Infections; Cardiovascular Diseases; Female; Hepator

2011
Is hydrophobia necessary for the hepatologist prescribing nonselective beta-blockers in cirrhosis?
    Hepatology (Baltimore, Md.), 2011, Volume: 53, Issue:6

    Topics: Adrenergic beta-Antagonists; Aged; Anti-Infective Agents; Ciprofloxacin; Dose-Response Relationship,

2011
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
    Hepatology (Baltimore, Md.), 2003, Volume: 37, Issue:4

    Topics: Antihypertensive Agents; Ascites; Bacterial Infections; Cohort Studies; Drug Therapy, Combination; F

2003
Propranolol does not affect incidence of spontaneous bacterial peritonitis in cirrhotic patients with ascites.
    The American journal of gastroenterology, 2003, Volume: 98, Issue:6

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Ascites; Bacterial Translocation; Esophageal and Gastric V

2003
Spontaneous bacterial peritonitis in cirrhotic patients: Is prophylactic propranolol therapy beneficial?
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Ascites; Ascitic Fluid; Bacterial Infections; Chi-Square Distribu

2006
[Prevention of variceal bleeding and measurement of hepatic vein pressure gradient].
    The Korean journal of hepatology, 2006, Volume: 12, Issue:3

    Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Esophageal and Gastric Varices; Gastrointest

2006
Neural and hormonal influences of peritonitis on paralytic ileus.
    The American surgeon, 1967, Volume: 33, Issue:10

    Topics: Animals; Dogs; Epinephrine; Gastrointestinal Motility; Intestinal Obstruction; Iodine; Kymography; P

1967
Sclerosing peritonitis with short-term propranolol therapy.
    Archives of internal medicine, 1980, Volume: 140, Issue:8

    Topics: Drug Eruptions; Eye Diseases; Humans; Peritonitis; Propranolol; Sclerosis

1980
Peritoneal sclerosis in peritoneal dialysis patients.
    American journal of nephrology, 1984, Volume: 4, Issue:3

    Topics: Adult; Humans; Male; Peritoneal Dialysis; Peritoneum; Peritonitis; Propranolol; Sclerosis

1984
Propranolol, oxprenolol, and sclerosing peritonitis.
    British medical journal (Clinical research ed.), 1982, Mar-20, Volume: 284, Issue:6319

    Topics: Adult; Aged; Female; Humans; Intestine, Small; Male; Middle Aged; Oxprenolol; Peritoneum; Peritoniti

1982
Sclerosing peritonitis and propranolol.
    Chest, 1981, Volume: 79, Issue:3

    Topics: Angina Pectoris; Colon; Gastrointestinal Hemorrhage; Humans; Hypertension; Male; Middle Aged; Perito

1981
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a beta-adrenoreceptor blocker.
    American heart journal, 1979, Volume: 98, Issue:2

    Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Bronchi; Central Nervous System Diseases; Deafnes

1979
Sclerosing peritonitis and propranolol.
    Archives of internal medicine, 1978, Volume: 138, Issue:9

    Topics: Adult; Conjunctivitis; Drug Eruptions; Humans; Male; Peritonitis; Propranolol; Sclerosis

1978
Propranolol antagonizes the anti-inflammatory effect of alcohol and improves survival of infected intoxicated rabbits.
    The Journal of clinical investigation, 1978, Volume: 62, Issue:3

    Topics: Alcoholic Intoxication; Animals; Anti-Inflammatory Agents; Cell Adhesion; Ethanol; Granulocytes; Hum

1978
Letter: Practolol reaction.
    The New Zealand medical journal, 1975, Jul-23, Volume: 82, Issue:544

    Topics: Female; Humans; Intestinal Obstruction; Middle Aged; Peritonitis; Practolol; Propranolol; Sclerosis

1975
Letter: Beta-blockers and fibrinous peritonitis.
    British medical journal, 1975, Jun-28, Volume: 2, Issue:5973

    Topics: Humans; Peritonitis; Practolol; Propranolol

1975
Letter: beta-blockers and fibrinous peritonitis.
    British medical journal, 1975, May-31, Volume: 2, Issue:5969

    Topics: Aged; Angina Pectoris; Female; Humans; Intestinal Obstruction; Peritonitis; Pleural Effusion; Practo

1975
[Hemosorption and endolymphatic therapy in the treatment of paralytic ileus in peritonitis and acute intestinal obstruction].
    Vestnik khirurgii imeni I. I. Grekova, 1990, Volume: 144, Issue:3

    Topics: Acute Disease; Aged; Female; Gastrointestinal Motility; Hemoperfusion; Humans; Injections, Intralymp

1990
Reflex adrenergic inhibition of colonic motility in anesthetized rat caused by nociceptive stimuli of peritoneum. An alpha 2-adrenoceptor-mediated response.
    Digestive diseases and sciences, 1985, Volume: 30, Issue:8

    Topics: Animals; Blood Pressure; Colon; Female; Gastrointestinal Motility; Heart Rate; Isoproterenol; Male;

1985
[Use of obsidan and potassium phosphate for correction of the oxygen transport function of the blood in peritonitis].
    Vestnik khirurgii imeni I. I. Grekova, 1987, Volume: 139, Issue:10

    Topics: Adolescent; Adult; Aged; Child; Drug Therapy, Combination; Humans; Infusions, Intravenous; Middle Ag

1987
Inhibition of gastrointestinal transit due to surgical trauma or peritoneal irritation is reduced in capsaicin-treated rats.
    Gastroenterology, 1986, Volume: 91, Issue:2

    Topics: Animals; Animals, Newborn; Capsaicin; Gastrointestinal Motility; Intestinal Obstruction; Intestines;

1986